At the same time, wearable sensors that provide seamless and noninvasive monitoring are expected to add a minimum sensing burden compared with other types of sensors, whereas the automation of management processes that today require the cognitive effort of the persons living with T1D (eg, insulin bolus calculation) or induce stress (eg, fear of hypoglycemia) is expected to lead to better quality of life and lower daily burden. The gene discussed is INS; the disease is Hypoglycemia.